MSO Money in Trump PACs May Fund Anti-Cannabis Senate Bid

The report: industry money, a hostile candidate

MJBizDaily reported on Oct. 5, 2026 that cannabis companies have donated millions to President Donald Trump's PACs, and those committees appear poised to spend some of it on a staunchly anti-cannabis Senate candidate.

That's the core of it. The signal we're working from is the MJBizDaily summary, and it doesn't break out which MSOs gave, how much each contributed, or how the candidate's race is structured. We're not going to guess at any of that. Pull the full MJBizDaily report for the donor-by-donor detail.

The word doing the work is "appear." Spending hasn't been fully documented, and PAC money is rarely traceable dollar for dollar from a given donor to a given race.

Why an MSO writes the check anyway

Operators that give to a president's committees are buying proximity to the executive branch, not endorsing every downstream expenditure.

The logic isn't mysterious. Multistate operators carry the heaviest federal tax burden in the sector, because Section 280E of the Internal Revenue Code bars businesses that traffic in Schedule I or II substances from deducting ordinary expenses. Relief depends on decisions made in the White House, the DEA and the Justice Department. If you run a balance sheet strained by 280E, you want a seat at that table.

In Spanish, the word is cabildeo: lobbying, but with the connotation of working the corridors rather than the floor. Giving to a PAC is cabildeo at its most transactional. It buys a phone call, not a vote.

Still, the math is hard to argue with. A donor can win executive-branch goodwill and lose Senate votes in the same fiscal quarter.

The fungibility problem

Once contributions land in a PAC, donors generally have limited say over which candidates ultimately benefit.

That's the structural trap here. A company may give to a committee because it expects friendly executive action on rescheduling or banking access, then discover the committee is spending to elect a senator who would vote against SAFE Banking-style legislation or any broader reform. Money is fungible. Intent isn't.

Operators face a real reputational question, too. Patients, employees and the independent license holders who compete with MSOs in states like California and Ohio can read this as the largest companies funding opponents of the plant they sell. Whether that stings depends on how much of the donor list becomes public and how the candidate's race develops.

For investors, the issue is governance. Shareholders in publicly traded MSOs may ask how political spending is vetted, who signs off, and whether any policy ties contributions to a candidate's stated position on cannabis. Those are fair questions. Few companies in the sector have published clear answers.

What it means beyond U.S. borders

A hostile Senate seat matters well outside the U.S. market, because federal law still governs whether Latin American cannabis can ever legally enter it.

I cover Colombia and Brazil, where producers have built licensed export operations in the hope that U.S. federal reform eventually opens an import channel. Under current federal law, cannabis imports aren't a lane for ordinary commercial flower or extract. Changing that would take Congress, not just an agency memo.

Colombian cultivators speak of cosecha and exportación as if the U.S. door is a matter of when. A single committed opponent in the Senate is a reminder it's a matter of who votes. Brazilian operators, working under ANVISA's medical framework, are watching the same variable from a different angle.

For full background on this story, see the CannIntel topic hub on MSO political donations in 2026.

The next signal to watch: Federal Election Commission filings that show exactly where the PAC money goes, and whether any MSO changes its giving after the MJBizDaily report. Those disclosures will say more than any press statement.